Filtered By:
Vaccination: Cancer Vaccines
Countries: USA Health

This page shows you your search results in order of date.

Order by Relevance | Date

Total 72 results found since Jan 2013.

Self-assembling Gn head ferritin nanoparticle vaccine provides full protection from lethal challenge of < em > Dabie bandavirus < /em > in aged ferrets
This study demonstrates that DBV GnH-FT nanoparticles provide an efficient vaccine efficacy in mouse and aged ferret models and should be an outstanding vaccine candidate targeted for the aged population against fatal DBV infection. IMPORTANCE Dabie bandavirus (DBV) is an emerging tick-borne virus that causes severe fever with thrombocytopenia syndrome (SFTS) in infected patients. Human SFTS symptoms progress from fever, fatigue, and muscle pain to the depletion of white blood cells and platelets with fatality rates up to 30%. The recent spread of its vector tick to over 20 states in the United States increases the potenti...
Source: Cancer Control - September 15, 2023 Category: Cancer & Oncology Authors: Dokyun Kim Eunha Kim Semi Kim Youseung Chung Chih-Jen Lai Inho Cha Sung-Dong Cho Yunseo Choi Xinghong Dai Stephanie Kim Seokmin Kang Mi-Jeong Kwak Ziyi Liu Younho Choi Su-Hyung Park Young Ki Choi Jae U Jung Source Type: research

Vaccination Is the Best Bet Against Drug-Resistant Superbugs — Experts
Experts encourage parents to vaccinate their children against typhoid to ensure that the child has access to clean drinking water. Credit: Zofeen Ebrahim/IPS By Zofeen EbrahimKARACHI, Jul 6 2023 (IPS) The first thing you notice about eight-month-old Manahil Zeeshan is how tiny she looks on the adult-size hospital bed at the government-run Sindh Institute of Child Health and Neonatology (SICHN) in Korangi, a neighbourhood in Karachi. Her right foot is taped with a cannula, and she whimpers incessantly. “I have been in and out of the hospital for the last seven days,” said Uzma Mohammad, Zeeshan’s mom, with worry lines...
Source: IPS Inter Press Service - Health - July 6, 2023 Category: International Medicine & Public Health Authors: Zofeen Ebrahim Tags: Africa Civil Society Development & Aid Editors' Choice Featured Headlines Health Humanitarian Emergencies Inequality Poverty & SDGs TerraViva United Nations IPS UN Bureau IPS UN Bureau Report Pakistan Source Type: news

Fight Aging! Newsletter, June 5th 2023
In conclusion, higher BMR might reduce lifespan. The underlying pathways linking to major causes of death and relevant interventions warrant further investigation. Betting Against Progress Turns Out Poorly, But Can Work in the Short Term in a Slow Field https://www.fightaging.org/archives/2023/06/betting-against-progress-turns-out-poorly-but-can-work-in-the-short-term-in-a-slow-field/ Setting oneself up as a spokesperson for "we will not achieve this goal", as the fellow noted here is choosing to do, is a bet against technological progress. A glance at any few decade period in the past two hundred year...
Source: Fight Aging! - June 4, 2023 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs

News at a glance: China ’s ethics oversight, ARPA-H’s new science, and $210 million for protein research
PUBLIC HEALTH FDA advisers back maternal RSV shot A vaccine aims to protect infants from respiratory syncytial virus, a leading cause of infant hospitalization. JAMIE KELTER DAVIS/ THE NEW YORK TIMES /REDUX A panel advising the U.S. Food and Drug Administration (FDA) last week recommended that it approve a vaccine given to pregnant people to protect infants from respiratory syncytial virus (RSV), which can cause severe lung infections. The vote was unanimous based on the efficacy of the vaccine, called RSVpreF and branded Abrysvo. Ten members of the panel also...
Source: Science of Aging Knowledge Environment - May 25, 2023 Category: Geriatrics Source Type: research

Gene-editing summit touts sickle cell success, while questions on embryo editing linger
After decades of living with often excruciating pain, Victoria Gray had to get used to a new sensation in recent years: waking up without it. “It may sound crazy, but I had to pinch myself to see was I still able to feel pain,” she says. Gray, a 37-year-old mother of four from Forest, Mississippi, who was born with sickle cell disease, arguably became the star of last week’s International Summit on Human Genome Editing in London when she spoke about her transformation. In 2019, she was the first person to undergo an experimental therapy in which blood stem cells were taken from her, altered with the ...
Source: Science of Aging Knowledge Environment - March 13, 2023 Category: Geriatrics Source Type: research

New STELARA ® (ustekinumab) Long-Term Data Support its Established Safety Profile in Inflammatory Bowel Disease and Durable Efficacy in Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, March 4, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced final pooled long-term safety results for STELARA® (ustekinumab) through five years in adults with moderately to severely active Crohn’s disease (CD) and four years in adults with moderately to severely active ulcerative colitis (UC), as well as final four-year clinical and endoscopic outcomes from the UNIFI long-term extension (LTE) study evaluating the efficacy of STELARA for the treatment of adults with moderately to severely active UC.1,2 These data are a part of Janssen’s 22 oral and poster ...
Source: Johnson and Johnson - March 4, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news

Janssen Presents Updated Data Demonstrating Improved Outcomes from the Use of Niraparib in Combination with Abiraterone Acetate Plus Prednisone as a First-Line Therapy in Patients with BRCA-Positive Metastatic Castration-Resistant Prostate Cancer
SAN FRANCISCO, February 16, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced updated results from the Phase 3 MAGNITUDE study evaluating the investigational use of niraparib, a highly selective poly (ADP-ribose) polymerase (PARP) inhibitor, in combination with abiraterone acetate plus prednisone (AAP) in patients with metastatic castration-resistant prostate cancer (mCRPC) with or without specific homologous recombination repair (HRR) gene alterations, including BRCA mutations. Results will be featured today in a Rapid Abstract Session (Abstract #170) at the American Society of Clinica...
Source: Johnson and Johnson - February 16, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news

Janssen Data at ASCO GU Support Ambition to Transform Treatment of Prostate and Bladder Cancer Through Precision Medicine and Early Intervention
RARITAN, N.J., February 13, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced plans to present more than 20 abstracts featuring seven oncology therapies from its robust portfolio and pipeline at the annual American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium, taking place in San Francisco on February 16-18. Building on more than a decade of leadership in the development of medicines for people diagnosed with GU cancers, Janssen will present data demonstrating its ambition to advance patient-centered treatment through precision medicine, real-world evidence a...
Source: Johnson and Johnson - February 13, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news

STELARA ® (ustekinumab) Demonstrated Sustained Symptomatic and Corticosteroid-Free Remission Through Four Years in Adults with Moderately to Severely Active Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 10, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced final data from the long-term extension (LTE) of the Phase 3 UNIFI study demonstrating efficacy and safety of STELARA® (ustekinumab) through four years of treatment in adult patients with moderately to severely active ulcerative colitis (UC).1 Among all patients who had achieved clinical responsea with STELARA during induction, 64.9 percent were in symptomatic remissionb after 44 weeks of maintenance. At week 200 (four years), this proportion of patients was 55.2 percent; the majority (96.4 percen...
Source: Johnson and Johnson - October 10, 2022 Category: Pharmaceuticals Source Type: news

Results of Novel Clinical Study of Guselkumab and Golimumab Combination Therapy Show Adults with Moderately to Severely Active Ulcerative Colitis Maintained Higher Rates of Clinical, Histologic, and Endoscopic Remission at Week 38
SPRING HOUSE, PENNSYLVANIA, October 10, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from an ongoing analysis of a Phase 2a clinical trial showing adults with moderately to severely active ulcerative colitis (UC) who received 12 weeks of combination induction therapy with guselkumab and golimumab, followed by a transition to guselkumab alone for maintenance, achieved a clinical remission ratea (based on the modified Mayo score [mMayo])b at week 38 of 47.9 percent, a higher rate than induction and maintenance treatment with either guselkumab alone (31.0 percent) or golimumab al...
Source: Johnson and Johnson - October 10, 2022 Category: Pharmaceuticals Source Type: news

Weekly Overseas Health IT Links –10th September, 2022.
This article is adapted fromVoices in the Code: A Story About People, Their Values, and the Algorithm They Made,out Sept. 8 from Russell Sage Foundation Press.In May 2021, I got a call I never expected. I was working on abook about A.I. ethics, focused on the algorithm that gives out kidneys to transplant patients in the United States. Darren Stewart —a data scientist from UNOS, the nonprofit that runs the kidney allocation process—was calling to get my take: How many decimal places should they include when calculating each patient’s allocation score? The score is an incredibly important number, given it determines w...
Source: Australian Health Information Technology - September 10, 2022 Category: Information Technology Authors: Dr David G More MB PhD Source Type: blogs

The Macro View – Health, Economics, and Politics and the Big Picture. What I Am Watching Here And Abroad.
August 04, 2022 Edition-----The war seems to grind on sadly and Pres. Biden is having a second round with COVID as unprecedented weather happens all over the US. It all feels rather like ‘the end of days’!In the UK we see an increasing chance of a third female PM being elected as the country seems to be struggling. We do need to remember however the UK remains a significant power with nuclear weapons and home-grown nuclear submarines!In OZ we have had last week working out how to progress the First Nations ‘Voice’ as we wrap up the 1st session of Parliament for the new Government. Comments welcome on how you think ...
Source: Australian Health Information Technology - August 4, 2022 Category: Information Technology Authors: Dr David G More MB PhD Source Type: blogs

STELARA ® (ustekinumab) Approved by the U.S. Food and Drug Administration to Treat Pediatric Patients with Active Psoriatic Arthritis
HORSHAM, PENNSYLVANIA, August 1, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved STELARA® (ustekinumab) for the treatment of pediatric patients six years of age and older with active psoriatic arthritis (PsA). This rare disease that resembles adult PsA affects five to eight percent of children and adolescents with chronic inflammatory arthritis.*1-7 Two of the four indications for STELARA now include pediatric patients, further expanding its treatment profile since the first approval in 2009 for adults living with moderate...
Source: Johnson and Johnson - August 1, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news

Abstracts of Presentations at the Association of Clinical Scientists 143 < sup > rd < /sup > Meeting Louisville, KY May 11-14,2022
Conclusion: These assays are suitable for routine diagnostic. The UltraFast NextGenPCR is the fastest with average time (30mins), followed by Agilent (2 hrs) and MassArray (6hrs). Upon completion of this activity, participants should be able to examine, measure and compare results from different assays for SARS detection, evaluate and diagnose accurately, as well as being able to plan, organize and recommend a diagnostic procedure for diagnostic laboratory. Key words: SARS-CoV-2, RNA extraction, RT-PCR, limit of detection, quantification cycle, COVID-19, in vitro diagnostic tests, Agilent, Massarray, Ultrafast. [20] From t...
Source: Annals of Clinical and Laboratory Science - July 1, 2022 Category: Laboratory Medicine Source Type: research